Mymd Pharmaceuticals (NASDAQ:QCLS) Announces Quarterly Earnings Results

Mymd Pharmaceuticals (NASDAQ:QCLS) posted its quarterly earnings results on Wednesday. The company reported ($0.79) earnings per share for the quarter, Zacks reports.

Mymd Pharmaceuticals Stock Performance

QCLS stock remained flat at $2.89 during mid-day trading on Wednesday. 48,502 shares of the company’s stock traded hands, compared to its average volume of 674,812. The stock has a market cap of $12.04 million, a PE ratio of -0.14 and a beta of 2.16. Mymd Pharmaceuticals has a twelve month low of $2.50 and a twelve month high of $10.79. The stock has a 50 day simple moving average of $3.48.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on QCLS. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a report on Friday. Wall Street Zen downgraded Mymd Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Mymd Pharmaceuticals Company Profile

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.